Bill Taranto

But at the time, we had invested in a company that was a technology that came out of Mayo.

And it was called Preventus Solutions.

And it was a company that created a medical device that looked like a Band-Aid that would sit on your chest and it would prevent AFib from happening or a stroke from happening.

And a very predictive product that would allow cardiologists to know in advance whether a patient was going into AFib that could then lead to a stroke.

And it was really revolutionary because it wasn't a halter monitor anymore.

It was a little Band-Aid sized patch that would sit on the chest.

But we started

the company with a $2 million investment by just licensing it out from Mayo.

And over time, what we ended up doing was we ended up buying an infrastructure company out of Texas that had a call center, had electrophysiologists on staff, had the ability from an infrastructure perspective to make the device, actually ship it out to the patient and the cardiologist.

and have a seamless sort of integrated solution.

It started with this large $140 million purchase that we made of a company called eCardio down in Texas that we merged into Preventus.

And then over time, we added a few more acquisitions, one around patient sort of almost patient advocacy or care continuation programs.

So once the patient was on the device, how do you manage the patient going forward?

We kept enhancing the call center where we could take then calls more on a global basis.

But we added four or five sort of different acquisitions over time to really build a company.

And over a 10 year period, we built a company from really a small two, $3 million revenue company into almost $170 million revenue company.

And then in 2021, we went to IPO and out of the blue, we

They were a very small partner of ours in the company, but Boston Scientific called and said, hey, instead of IPOing, would you consider selling to us?

And we said, yeah, we ended up selling it for $1.5 billion to them.

And we had owned around 60% of the company.